Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database

Zsuzsanna Kurti, Zsuzsanna Vegh, Petra A. Golovics, Petra Fadgyas-Freyler, Krisztina B. Gecse, Lorant Gonczi, Judit Gimesi-Orszagh, Barbara D. Lovasz, P. Lakatos

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases associated with a substantial healthcare utilization. Aim Our aim was to estimate the national prevalence of inflammatory bowel disease (IBD), CD and UC and to describe current drug treatment practices in CD and UC. Methods Patients and drug dispensing events were identified according to international classification codes for UC and CD in in-patient care, non-primary out-patient care and drug prescription databases (2011–2013) of the National Health Insurance Fund. Results A total of 55,039 individuals (men: 44.6%) with physician-diagnosed IBD were alive in Hungary in 2013, corresponding to a prevalence of 0.55% (95% CI, 0.55–0.56). The prevalence of CD 0.20% (95% CI, 0.19–0.20), and UC was 0.34% (95% CI, 0.33–0.34). The prevalence both in men and women was the highest in the 20–39 year-olds in CD. Current use of immunosuppressives and biological therapy was highest in the pediatric CD population (44% and 15%) followed by adult CD (33% and 9%), while their use was lowest in elderly patients. Interestingly, current use of 5-ASA (5-aminosalicylates) was high in both UC and CD irrespective of the age group. Conclusions The Hungarian IBD prevalence based on nationwide database of the National Health Insurance Fund was high. We identified significant differences in the drug prescription practices according to age-groups.

Original languageEnglish
Pages (from-to)1302-1307
Number of pages6
JournalDigestive and Liver Disease
Volume48
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Hungary
National Health Programs
Inflammatory Bowel Diseases
Crohn Disease
Ulcerative Colitis
Databases
Pharmaceutical Preparations
Population
Drug Prescriptions
Therapeutics
Age Groups
Pharmaceutical Databases
Mesalamine
Biological Therapy
Immunosuppressive Agents
Patient Care
Chronic Disease
Outpatients
Delivery of Health Care
Physicians

Keywords

  • Drug treatment strategy
  • Epidemiology
  • Inflammatory bowel disease
  • Prevalence
  • Public health registry data

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary : A population-based study based on the National Health Insurance Fund database. / Kurti, Zsuzsanna; Vegh, Zsuzsanna; Golovics, Petra A.; Fadgyas-Freyler, Petra; Gecse, Krisztina B.; Gonczi, Lorant; Gimesi-Orszagh, Judit; Lovasz, Barbara D.; Lakatos, P.

In: Digestive and Liver Disease, Vol. 48, No. 11, 01.11.2016, p. 1302-1307.

Research output: Contribution to journalArticle

Kurti, Zsuzsanna ; Vegh, Zsuzsanna ; Golovics, Petra A. ; Fadgyas-Freyler, Petra ; Gecse, Krisztina B. ; Gonczi, Lorant ; Gimesi-Orszagh, Judit ; Lovasz, Barbara D. ; Lakatos, P. / Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary : A population-based study based on the National Health Insurance Fund database. In: Digestive and Liver Disease. 2016 ; Vol. 48, No. 11. pp. 1302-1307.
@article{82cb73b438784195bf150c94f9433cee,
title = "Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database",
abstract = "Background Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases associated with a substantial healthcare utilization. Aim Our aim was to estimate the national prevalence of inflammatory bowel disease (IBD), CD and UC and to describe current drug treatment practices in CD and UC. Methods Patients and drug dispensing events were identified according to international classification codes for UC and CD in in-patient care, non-primary out-patient care and drug prescription databases (2011–2013) of the National Health Insurance Fund. Results A total of 55,039 individuals (men: 44.6{\%}) with physician-diagnosed IBD were alive in Hungary in 2013, corresponding to a prevalence of 0.55{\%} (95{\%} CI, 0.55–0.56). The prevalence of CD 0.20{\%} (95{\%} CI, 0.19–0.20), and UC was 0.34{\%} (95{\%} CI, 0.33–0.34). The prevalence both in men and women was the highest in the 20–39 year-olds in CD. Current use of immunosuppressives and biological therapy was highest in the pediatric CD population (44{\%} and 15{\%}) followed by adult CD (33{\%} and 9{\%}), while their use was lowest in elderly patients. Interestingly, current use of 5-ASA (5-aminosalicylates) was high in both UC and CD irrespective of the age group. Conclusions The Hungarian IBD prevalence based on nationwide database of the National Health Insurance Fund was high. We identified significant differences in the drug prescription practices according to age-groups.",
keywords = "Drug treatment strategy, Epidemiology, Inflammatory bowel disease, Prevalence, Public health registry data",
author = "Zsuzsanna Kurti and Zsuzsanna Vegh and Golovics, {Petra A.} and Petra Fadgyas-Freyler and Gecse, {Krisztina B.} and Lorant Gonczi and Judit Gimesi-Orszagh and Lovasz, {Barbara D.} and P. Lakatos",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.dld.2016.07.012",
language = "English",
volume = "48",
pages = "1302--1307",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary

T2 - A population-based study based on the National Health Insurance Fund database

AU - Kurti, Zsuzsanna

AU - Vegh, Zsuzsanna

AU - Golovics, Petra A.

AU - Fadgyas-Freyler, Petra

AU - Gecse, Krisztina B.

AU - Gonczi, Lorant

AU - Gimesi-Orszagh, Judit

AU - Lovasz, Barbara D.

AU - Lakatos, P.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases associated with a substantial healthcare utilization. Aim Our aim was to estimate the national prevalence of inflammatory bowel disease (IBD), CD and UC and to describe current drug treatment practices in CD and UC. Methods Patients and drug dispensing events were identified according to international classification codes for UC and CD in in-patient care, non-primary out-patient care and drug prescription databases (2011–2013) of the National Health Insurance Fund. Results A total of 55,039 individuals (men: 44.6%) with physician-diagnosed IBD were alive in Hungary in 2013, corresponding to a prevalence of 0.55% (95% CI, 0.55–0.56). The prevalence of CD 0.20% (95% CI, 0.19–0.20), and UC was 0.34% (95% CI, 0.33–0.34). The prevalence both in men and women was the highest in the 20–39 year-olds in CD. Current use of immunosuppressives and biological therapy was highest in the pediatric CD population (44% and 15%) followed by adult CD (33% and 9%), while their use was lowest in elderly patients. Interestingly, current use of 5-ASA (5-aminosalicylates) was high in both UC and CD irrespective of the age group. Conclusions The Hungarian IBD prevalence based on nationwide database of the National Health Insurance Fund was high. We identified significant differences in the drug prescription practices according to age-groups.

AB - Background Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases associated with a substantial healthcare utilization. Aim Our aim was to estimate the national prevalence of inflammatory bowel disease (IBD), CD and UC and to describe current drug treatment practices in CD and UC. Methods Patients and drug dispensing events were identified according to international classification codes for UC and CD in in-patient care, non-primary out-patient care and drug prescription databases (2011–2013) of the National Health Insurance Fund. Results A total of 55,039 individuals (men: 44.6%) with physician-diagnosed IBD were alive in Hungary in 2013, corresponding to a prevalence of 0.55% (95% CI, 0.55–0.56). The prevalence of CD 0.20% (95% CI, 0.19–0.20), and UC was 0.34% (95% CI, 0.33–0.34). The prevalence both in men and women was the highest in the 20–39 year-olds in CD. Current use of immunosuppressives and biological therapy was highest in the pediatric CD population (44% and 15%) followed by adult CD (33% and 9%), while their use was lowest in elderly patients. Interestingly, current use of 5-ASA (5-aminosalicylates) was high in both UC and CD irrespective of the age group. Conclusions The Hungarian IBD prevalence based on nationwide database of the National Health Insurance Fund was high. We identified significant differences in the drug prescription practices according to age-groups.

KW - Drug treatment strategy

KW - Epidemiology

KW - Inflammatory bowel disease

KW - Prevalence

KW - Public health registry data

UR - http://www.scopus.com/inward/record.url?scp=84992494143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992494143&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2016.07.012

DO - 10.1016/j.dld.2016.07.012

M3 - Article

C2 - 27481587

AN - SCOPUS:84992494143

VL - 48

SP - 1302

EP - 1307

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 11

ER -